A detailed history of Dimensional Fund Advisors LP transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 1,103,820 shares of ARCT stock, worth $42.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,103,820
Previous 1,088,930 1.37%
Holding current value
$42.8 Million
Previous $34.3 Million 8.57%
% of portfolio
0.01%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$31.23 - $42.99 $465,014 - $640,121
14,890 Added 1.37%
1,103,820 $37.3 Million
Q4 2023

Feb 07, 2024

BUY
$17.71 - $32.97 $2.04 Million - $3.79 Million
115,087 Added 11.82%
1,088,930 $34.3 Million
Q3 2023

Nov 09, 2023

BUY
$25.44 - $37.35 $7.1 Million - $10.4 Million
278,989 Added 40.15%
973,843 $24.9 Million
Q2 2023

Aug 09, 2023

BUY
$23.94 - $32.36 $4.99 Million - $6.74 Million
208,233 Added 42.79%
694,854 $19.9 Million
Q1 2023

May 12, 2023

BUY
$14.72 - $23.97 $2.7 Million - $4.4 Million
183,760 Added 60.67%
486,621 $11.7 Million
Q4 2022

Feb 09, 2023

BUY
$14.14 - $23.06 $2.26 Million - $3.68 Million
159,743 Added 111.62%
302,861 $5.14 Million
Q3 2022

Nov 10, 2022

SELL
$13.05 - $22.13 $81,875 - $138,843
-6,274 Reduced 4.2%
143,118 $2.12 Million
Q2 2022

Aug 12, 2022

SELL
$12.26 - $31.17 $835,886 - $2.13 Million
-68,180 Reduced 31.34%
149,392 $2.35 Million
Q1 2022

May 13, 2022

BUY
$17.64 - $39.57 $2.52 Million - $5.64 Million
142,633 Added 190.33%
217,572 $5.87 Million
Q4 2021

Feb 09, 2022

BUY
$34.2 - $47.56 $2.56 Million - $3.56 Million
74,939 New
74,939 $2.77 Million

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $1.03B
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.